DTG

New results from the D3 (PENTA-21) trial, sponsored by Fondazione Penta ETS, add to the evidence that dolutegravir-based treatment remains a strong option for children living with HIV,

Laurus Labs has submitted an application to the US Food and Drug Administration (FDA) for the tentative approval of paediatric Darunavir/ritonavir (pDRV/r (120/20 mg)). UNIVERSAL is the first product development project from the World Health Organisation’s (WHO) GAP-F project which was established to promote the development of safer,